Product Pathways
BCP0111 SB202190
SB202190 (FHPI) is a potent p38 MAPK inhibitor targeting p38α and p38β with IC50 of 50 nM and 100 nM, respectively.
BCP0112 SB203580
SB203580 is a p38 MAPK inhibitor with IC50 of 0.3-0.5 μM and blocks PKB phosphorylation with IC50 of 3-5 μM.
BCP0136 VX702
VX-702, one of a series of second-generation, orally active p38 MAP kinase inhibitors, for the potential treatment of inflammation, rheumatoid arthritis and cardiovascular diseases.
BCP0171 BIRB 796(Doramapimod)
BIRB 796 (Doramapimod) is a highly selective p38α MAPK inhibitor.
BCP0253 R1487
R1487 is a potently p38α inhibitor.
BCP0258 SD 169
Selective, orally active, ATP-competitive inhibitor of p38α MAPK.
BCP0259 TAK-715
Inhibitor of p38 MAPK (IC50 = 7.1 nM for p38 MAPKα).
BCP0261 RWJ67657
Selective p38α and p38β inhibitor.
BCP0341 LY2228820
LY2228820 (LY) is a novel and potent p38MAPK inhibitor.
BCP0407 AS703026
AS703026 is a novel, selective, orally bioavailable MEK1/2 inhibitor, in human multiple myeloma (MM).
第一页 1 2 最后页 
Only for research purpose , not for human consumption Copyright©2012 ShangHai Biochempartner Co.,Ltd.